Better Health for All

Phathom Pharmaceuticals' core business is developing and commercializing treatments for gastrointestinal diseases, including vonoprazan for acid-related disorders, H. pylori infection, and erosive esophagitis.

These products are designed to provide substantial health benefits, with no evidence of products causing net negative health outcomes, indicating that 90-95% of its portfolio delivers substantial health benefits. The company has no revenue from products with established negative health outcomes. However, its product, VOQUEZNA, has notable safety incidents, including contraindications, warnings, precautions, and adverse reactions such as gastritis (6%), abdominal pain (4%), and diarrhea (5%) in various indications, which are explicitly listed. The company demonstrates strong risk transparency by disclosing extensive contraindications, warnings, precautions, adverse reactions, and drug interactions for VOQUEZNA. It also makes clinical trial information, including eligibility criteria, available on ClinicalTrials.gov and encourages reporting of suspected violations. For healthcare data responsibility, the company maintains confidentiality of entrusted information and safeguards it, and its clinical trials are registered on ClinicalTrials.gov. In terms of clinical trial ethics, the company's clinical research adheres to regulatory requirements, is conducted with respect for participants, and includes randomized, double-blind, placebo-controlled studies. Phathom Pharmaceuticals has in-licensed exclusive rights to vonoprazan in the U.S., Europe, and Canada, and does not currently make investigational products available through expanded access programs, indicating limited patent flexibility.

Fair Money & Economic Opportunity

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases.

Its core business does not involve lending, deposit services, or other financial products. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness (APRs/fees), exploitative fee exposure, inclusion initiatives (loan/insurance book), data accessibility (customer finance data), fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, and geographic inclusion (banking deserts), are not applicable to the company's operations. Similarly, product simplicity, as defined by readability standards for financial product disclosures, is not relevant to a pharmaceutical product.

Fair Pay & Worker Respect

The CEO's 2023 compensation was $3,411,022, while the average U.S. worker earned $65,470 in the same year, resulting in a CEO to median employee pay ratio of approximately 52:1.

Approximately 9 out of 10 employees surveyed rated the company as a great place to work. The company offers two health insurance plans, Meritain Open Access Plan (PPO) and Meritain Open Access HSA Plan, with Phathom contributing 100% of the deductible for the HSA plan ($2,000 for individual, $4,000 for family) and covering 100% of in-network coinsurance after deductible for both plans.

Honest & Fair Business

Phathom Pharmaceuticals has a 'Reporting Suspected Law & Company Policy Violations (i.e., Whistleblower) Policy' with a 24/7 anonymous compliance hotline and a prohibition against retaliation.

However, there is no explicit evidence of independent investigation processes for these reports. The company's board of directors has eight out of nine members deemed independent, which is approximately 89% conflict-free. Phathom maintains an 'Anti-corruption & Anti-bribery Law Compliance Policy' and states it has instituted and maintains policies and procedures designed to promote and achieve continued compliance with Anti-Corruption Laws, including the FCPA, and that its operations are conducted in compliance with applicable anti-money laundering laws and sanctions. The company engages Ernst & Young LLP as its independent registered public accounting firm and uses Pay Governance LLC, an independent third-party compensation consulting firm. Additionally, a revenue interest financing agreement allows for audits of the company's books by an independent public accounting firm to verify royalty payments, and the company relies on certificates of analysis from suppliers with potential for independent third-party laboratory dispute resolution.

Planet-Friendly Business

No specific, quantitative data points or factual evidence related to any of the Planet-Friendly Business KPIs were found in the provided articles. explicitly states that no quantitative data related to specific ESG metrics such as emissions, renewable energy, or water use is available for Phathom Pharmaceuticals, Inc.

The other articles focus on financial results and regulatory updates, without environmental performance details.

Safe & Smart Tech

Phathom Pharmaceuticals, Inc. reported no material cybersecurity incidents and no prior incidents materially affecting its operations, business strategy, results, or financial condition in its 2024-03-07 10-K filing.

The company conducts cybersecurity awareness training for employees, incident response personnel, and senior management. It also has vulnerability management processes in place, including risk assessments to identify material cybersecurity risks. Additionally, the company utilizes external service providers for security assessments and testing.